Erlotinib as Second-Line Therapy for Patients with Advanced Non-Small-Cell Lung Cancer and Wild-Type EGFR Tumors. J. Anal. Oncol. [Internet]. 2015 Jun. 20 [cited 2026 Apr. 16];4(3): 94-101. Available from: https://www.neoplasiaresearch.com/index.php/jao/article/view/250